The antibody response to Plasmodium falciparum Merozoite Surface Protein 4: Comparative assessment of specificity and growth inhibitory antibody activity to infection-acquired and immunization-induced epitopes

Malaria Journal

Volumn 10, Issue , 2011, Pages

  De Silva, Harini D ^a   Saleh, Suha ^a   Kovacevic, Svetozar ^a   Wang, Lina ^a   Black, Casilda G ^a   Plebanski, Magdalena ^a   Coppel, Ross L ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPITOPE; FREUND ADJUVANT; MALARIA VACCINE; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; PARASITE ANTIGEN; PLASMODIUM FALCIPARUM MEROZOITE SURFACE PROTEIN 4; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; MEROZOITE SURFACE PROTEIN 4, PLASMODIUM; PROTOZOAL PROTEIN; PROTOZOON ANTIBODY; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; CARBOXY TERMINAL SEQUENCE; COMPARATIVE STUDY; CONTROLLED STUDY; CONVALESCENCE; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; GROWTH INHIBITION; HUMAN; HUMORAL IMMUNITY; IMMUNIZATION; IN VITRO STUDY; INFECTION; MALARIA FALCIPARUM; MOUSE; NONHUMAN; PLASMODIUM FALCIPARUM; PROTEIN EXPRESSION; ANIMAL; BAGG ALBINO MOUSE; BLOOD; EPITOPE MAPPING; GROWTH, DEVELOPMENT AND AGING; HUMAN EXPERIMENT; IMMUNOLOGY; ISOLATION AND PURIFICATION; METHODOLOGY; RABBIT; VIET NAM;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; EPITOPES, B-LYMPHOCYTE; HUMAN EXPERIMENTATION; HUMANS; IMMUNIZATION; MALARIA VACCINES; MALARIA, FALCIPARUM; MICE; MICE, INBRED BALB C; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; RABBITS; RECOMBINANT PROTEINS; VIETNAM;

EID: 80052833040     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-10-266     Document Type: Article

References (41)

1. Vaccinating with the genome: a Sisyphean task? Coppel R, Trends Parasitol 2009 25 205 212 10.1016/j.pt.2009.02.006 19359219
2. A second merozoite surface protein (MSP-4) of Plasmodium falciparum that contains an epidermal growth factor-like domain. Marshall VM, Silva A, Foley M, Cranmer S, Wang L, McColl DJ, Kemp D, Coppel RL, Infect Immun 1997 65 4460 4467 9353020 (Pubitemid 27463212)
3. Identification and Stoichiometry of Glycosylphosphatidylinositol-anchored Membrane Proteins of the Human Malaria Parasite Plasmodium falciparum. Gilson PR, Nebl S, Vukcevic D, Moritz RL, Sargeant T, Speed TP, Schofield L, Crabb BS, Mol Cell Proteomics 2006 5 1286 1299 10.1074/mcp.M600035-MCP200 16603573 (Pubitemid 44103399)
4. A Set of Glycosylphosphatidyl Inositol-Anchored Membrane Proteins of Plasmodium falciparum Is Refractory to Genetic Deletion. Sanders PR, Kats LM, Drew DR, O'Donnell RA, O'Neill M, Maier AG, Coppel RL, Crabb BS, Infect Immun 2006 74 4330 4338 10.1128/IAI.00054-06 16790807 (Pubitemid 43993366)
5. Structural and Antigenic Properties of merozoite surface protein 4 of Plasmodium falciparum. Wang L, Black CG, Marshall VM, Coppel RL, Infect Immun 1999 67 2193 2200 10225874 (Pubitemid 29200472)
6. Naturally Acquired Antibody Responses to Plasmodium falciparum Merozoite Surface Protein 4 in a Population Living in an Area of Endemicity in Vietnam. Wang L, Richie TL, Stowers A, Nhan DH, Coppel RL, Infect Immun 2001 69 4390 4397 10.1128/IAI.69.7.4390-4397.2001 11401978 (Pubitemid 32574437)
7. Limited polymorphism of the vaccine candidate merozoite surface protein 4 of Plasmodium falciparum. Wang L, Marshall VM, Coppel RL, Mol Biochem Parasitol 2002 120 301 303 10.1016/S0166-6851(01)00457-1 11897136 (Pubitemid 34233795)
8. Diversity of Plasmodium falciparum vaccine candidate merozoite surface protein 4 (MSP4) in a natural population. Benet A, Tavul L, Reeder J, Cortes A, Mol Biochem Parasitol 2004 134 275 280 10.1016/j.molbiopara.2003.12.005 15003847 (Pubitemid 38299368)
9. Gene Polymorphisms of Plasmodium falciparum merozoite surface proteins 4 and 5. Polson HE, Conway DJ, Fandeur T, Mercereau-Puihalon O, Longacre S, Mol Biochem Parasitol 2005 142 110 115 10.1016/j.molbiopara.2005.02.009 15878789 (Pubitemid 40720134)
10. Immunisation with recombinant Plasmodium yoelii merozoite surface protein 4/5 protects mice against lethal challenge. Kedzierski L, Black CG, Coppel RL, Infect Immun 2000 68 6034 6037 10.1128/IAI.68.10.6034-6037.2000 10992516
11. Merozoite Surface Protein 4/5 Provides Protection against Lethal Challenge with a Heterologous Malaria Parasite Strain. Goschnick MW, Black CG, Kedzierski L, Holder AA, Coppel RL, Infect Immun 2004 72 5840 5849 10.1128/IAI.72.10.5840-5849.2004 15385485 (Pubitemid 39303696)
12. Immunisation with a combination of merozoite surface proteins 4/5 and 1 enhances protection against lethal challenge with Plasmodium yoelii. Kedzierski L, Black CG, Goschnick MW, Stowers AW, Coppel RL, Infect Immun 2002 70 6066 6613
13. Differences in epitope recognition, isotype and titre of antisera to Plasmodium falciparum merozoite surface protein 4 raised by different modes of DNA or protein immunisation. Wang L, Menting JGT, Black CG, Stowers A, Kaslow DC, Hoffman SL, Coppel RL, Vaccine 2000 19 816 824 10.1016/S0264-410X(00)00245-0 11115704
14. Continuous cultures of fused cells secreting antibody of predefined specificity. Kohler G, Milstein C, Nature 1975 256 495 497 10.1038/256495a0 1172191
15. Identification of the Plasmodium chabaudi Homologue of Merozoite Surface Proteins 4 and 5 of Plasmodium falciparum. Black CG, Wang L, Hibbs A, Werner E, Coppel RL, Infecti Immun 1999 67 2075 2081 (Pubitemid 29200455)
16. Passive Immunisation with Antibodies against Three Distinct Epitopes on Plasmodium yoelii Merozoite Surface Protein 1 Suppresses Parasitemia. Spencer Valero L, Solabomi A, Ogun S, Fleck S, Ling I, TJ S-F, Blackman M, Holder A, Infection and Immunity 1998 66 8 3925 3930 9673281 (Pubitemid 28347856)
17. 19, the carboxy-terminal fragment of the major merozoite surface protein of Plasmodium falciparum. Egan A, Chappel J, Burghaus P, Morris J, McBride J, Holder A, Kaslow D, Riley E, Infect Immun 1995 63 456 466 7822010
18. The Relative Affinity of Recombinant Dihydrolipomide Transacetylase for Autoantibodies in Primary Biliary Cirrhosis. Robertson CA, Coppel RL, Prindiville T, Fregeau D, Kaplan M, Dickson RE, Gershwin ME, Hepatology 1990 11 717 722 10.1002/hep.1840110502 2347544 (Pubitemid 20191374)
19. Human antibodies to the 19 kDa C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 inhibit parasite growth in vitro. Egan A, Burghaus P, Druilhe P, Holder A, Riley E, Parasite Immunol 1999 21 133 139 10.1046/j.1365-3024.1999.00209.x 10205793 (Pubitemid 29118866)
20. Structural studies on Plasmodium vivax merozoite surface protein-1. Babon JJ, Morgan WD, Kelly G, Eccleston JF, Feeney J, Holder AA, Mol Biochem Parasitol 2007 153 31 40 10.1016/j.molbiopara.2007.01.015 17343930 (Pubitemid 46517672)
21. Immune effector mechanisms in malaria. Good M, Doolan DL, Curr Opin Immunol 1999 11 412 419 10.1016/S0952-7915(99)80069-7 10448141 (Pubitemid 29377908)
22. Gamma-globulin and acquired immunity to human malaria. Cohen J, McGregor I, Carrington S, Nature 1961 192 733 737 10.1038/192733a0 13880318
23. Breadth and Magnitude of Antibody Responses to Multiple Plasmodium falciparum Merozoite Antigens Are Associated with Protection from Clinical Malaria. Osier FHA, Fegan G, Polley SD, Murungi L, Verra F, Tetteh KKA, Lowe B, Mwangi T, Bull PC, Thomas AW, Cavanagh DR, McBride JS, Lanar DE, Mackinnon MJ, Conway DJ, Marsh K, Infect Immun 2008 76 2240 2248 10.1128/IAI.01585-07 18316390 (Pubitemid 351656161)
24. 19Are a Major Component of the Invasion-inhibitory Response in Individuals Immune to Malaria. O'Donnel RA, de Koning-Ward TF, Burt RA, Bockarie M, Reeder JC, Cowman AS, Crabb BS, J Exp Med 2001 193 1403 1412 10.1084/jem.193.12.1403 11413195 (Pubitemid 32565969)
25. 19, Predicts Protection from Malaria Infection and High-Density Parasitaemia. Okech BA, Corran PH, Todd J, Joynson-Hicks A, Uthaipibull C, Egwang TG, Holder AA, Riley EM, Infect Immun 2004 72 1557 1567 10.1128/IAI.72.3.1557-1567.2004 14977962 (Pubitemid 38263778)
26. Human antibodies to recombinant protein constructs of Plasmodium falciparum Apical Membrane Antigen 1 (AMA1) and their associations with protection from malaria. Polley SD, Mwangi T, Kocken CH, Thomas AW, Dutta S, Lanar DE, Remarque E, Ross A, Williams TN, Mwanbingu G, Lowe B, Conway DJ, Marsh K, Vaccine 2004 23 718 728 10.1016/j.vaccine.2004.05.031 15542195 (Pubitemid 39473204)
27. Apical Membrane antigen 1: a malaria vaccine candidate in review. Remarque EJ, Faber BW, Clemens HM, Kocken C, Thomas AW, Trends Parasitol 2007 24 74 84
28. Disruption of disulfide linkages of the Plasmodium falciparum circumsporozoite protein:effects on cytotoxic and antibody responses in mice. Rathore D, Kumar S, Lanar DE, McCutchan TF, Mol Biocheml Parasitol 2001 118 75 82 10.1016/S0166-6851(01)00369-3 (Pubitemid 33043822)
29. Comparison of immunogenicity of five MSP1-based malaria vaccine candidate antigens in rabbits. Reed ZH, Kieny MP, Engers H, Friede M, Chang S, Longacre S, Malhotra P, Pan W, Long C, Vaccine 2009 27 1651 1660 10.1016/j.vaccine.2008. 10.093 19038302
30. High-Level Expression of the Malaria Blood-Stage Vaccine Candidate Plasmodium falciparum Apical Membrane Antigen 1 and Induction of Antibodies That Inhibit Erythrocyte Invasion. Kocken CHM, Withers-Martinez C, Dubbeld MA, van der Wel A, Hackett F, Blackman MJ, Thomas AW, Infect Imm 2002 70 8 4471 4476 10.1128/IAI.70.8.4471-4476.2002 (Pubitemid 34790958)
31. Comparison of Biological Activity of Human Anti-Apical Membrane Antigen-1 Antibodies Induced by Natural Infection and Vaccination. Miura K, Zhou H, Moretz SE, Diouf A, Thera MA, Dolo A, Doumbo O, Malkin E, Diemert D, Miller LH, Mullen GED, Long C, JImmunol 2008 181 8776 8783
32. Analysis of Antibodies Directed against Merozoite Surface Protein 1 of the Human Malaria Parasite Plasmodium falciparum. Woelbier U, Epp C, Kauth CW, Lutz R, Long CA, Coulibaly B, Kouyate B, Arevalo-Herrera M, Herrera S, Bujard H, Infect Immun 2006 74 1313 1322 10.1128/IAI.74.2.1313-1322.2006 16428781 (Pubitemid 43185571)
33. Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine. Ockenhouse CF, Angov E, Kester KE, Diggs C, Soisson L, Cummings JF, Stewart AV, Palmer DR, Mahajan B, Krzych U, Tornieporth N, Delchambre M, Vanhandenhove M, Ofori-Anyinam O, Cohen J, Lyon JA, Heppner DG, Vaccine 2006 24 3009 3017 10.1016/j.vaccine.2005.11.028 16356603
34. Phase1/2a Study of the Malaria Vaccine Candidate Apical Membrance Antigen-1 (AMA-1) Administered in Adjuvant System ASO1B or ASO2A. Spring MD, Cummings JF, Ockenhouse CF, Dutta S, Reidler R, Angov E, Bergmann-Leitner E, Stewart VA, Bittner S, Juompan L, Kortepeter MG, Nielson R, Krzych U, Tierney E, Ware LA, Dowler M, Hermsen CC, Sauerwein RW, de Vlas SJ, Ofori-Anyinam O, Lanar DE, Williams JL, Kester KE, Tucker K, Shi M, Malkin E, Long C, Diggs CL, Soisson L, Dubois MC, Ballou WR, Cohen J, Heppner DG, PLos One 2009 4 5254 10.1371/journal.pone.0005254 19390585
35. Mechanims Underlying the Monocyte-mediated Antibody-dependent Killing of Plasmodium falciparum Asexual Blood Stages. Bouharoun-Tayoun H, Oeuvray C, Lunel F, Druilhe P, J Exp Med 1995 182 409 417 10.1084/jem.182.2.409 7629503
36. A Novel Antibody-Dependent Cellular Cytotoxocity Mechanism Involved in Defense against Malaria Requires Costimulation of Monocytes Fc{gamma}RII and Fc{gamma}RIII. Jafarshad A, Dziegiel MH, Lundquist R, Nielsen LK, Singh S, Druilhe PL, J Immunol 2007 178 3099 3106 17312157 (Pubitemid 46333191)
37. identification of a conserved region of Plasmodium falciparum MSP3 targetted by biological active antibodies to improve vaccine design. Singh S, Soe S, Mejia J, Roussilhon C, Theisen M, Corradin G, Druilhe P, J Infect Dis 2004 190 1010 1018 10.1086/423208 15295710 (Pubitemid 39120982)
38. Glutamate-rich protein (GLURP) induces antibodies that inhibit in vitro growth of Plasmodium falciparum in a phase 1 malaria vaccine trial. Hermsen C, Verhage D, Telgt D, Teelan K, Bousema J, Roestenberg M, Bolad A, Berzins K, Giampietro C, Leroy O, et al. Vaccine 2007 25 2930 2940 10.1016/j.vaccine.2006. 06.081 16914240 (Pubitemid 46412561)
39. Naturally acquired cellular and humoral immune responses to the major merozoite surface antigen (PfMSP1) of Plasmodium falciparum are associated with reduced malaria morbidity. Riley EM, Allen SJ, Wheeler JG, Blackman MJ, Bennet S, Takacs B, Schofield L, Holder AA, Greenwood BM, Parasite Immunol 1992 14 321 337 10.1111/j.1365-3024.1992.tb00471.x 1625908
40. Dendritic Cells Induce Immunity and Long-Lasting Protection against Blood-Stage Malaria despite an In Vitro Parasite-Induced Maturation Defect. Pouniotis DS, Proudfoot O, Bogdanoska V, Apostolopoulos V, Fifis T, Plebanski M, Infect Immun 2004 72 5331 5339 10.1128/IAI.72.9.5331-5339.2004 15322030 (Pubitemid 39223421)
41. An empirical method for the prediction of T-cell epitopes. Davenport MP, Ho Shon IA, Hill AV, Immunogenetics 1995 42 392 397 7590973